Cocrystal Pharma (COCP) executive compensation, 2026 proxy

James Martin, Co-Chief Executive Officer and Chief Financial Officer, was paid $265,000 in 2025, down 61% from $680,859 the year before.

Open COCP in Gloom →
Cocrystal Pharma's chart, financials and news, free in your browser.Open COCP in Gloom →
Filed
May 27, 2026
Annual meeting
July 14, 2026
Pay year
2025
Named executives
2
CEO total pay
$265,000-61% vs prior year
Martin compensation paid
$265,0052025 compensation actually paid
Year-end RSUs
15,000Each executive
RSU market value
$14,685Each executive
2025 net loss
$(8,831,000)
Fixed-$100 investment TSR
95.112025 performance

How Martin was paid

$265,000 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary100%

Named executive officers

ExecutiveTotal
James MartinCo-Chief Executive Officer and Chief Financial Officer$265,000
Sam LeeCo-Chief Executive Officer and President$248,672

What changed and why

  • $265K2025 salary was $265,000 for James Martin and $248,672 for Sam Lee, with no separately reported bonus or equity awards.
  • $681K2024 total compensation was $680,859 for each co-CEO, versus $265,000 and $248,672 in 2025.
  • $250K$250,000 base salaries took effect January 1, 2025, reduced from $416,000 for each co-CEO.
  • $14,68515,000 RSUs valued at $14,685 remained outstanding for each executive at year-end.
  • $265K$265,005 was compensation actually paid to Martin in 2025, compared with $248,672 for Lee.
  • $8.8M$8,831,000 was the 2025 net loss, while fixed-$100 investment TSR was 95.11.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.